-
公开(公告)号：US10137207B2
公开(公告)日：2018-11-27
申请号：US14919967
申请日：2015-10-22
Applicant: MediBeacon Inc.
Inventor： Richard B. Dorshow , Raghavan Rajagopalan , Dennis A. Moore , Scott T. Depierro
Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
-
12.发明申请公开(公告)号：US20160331862A1
公开(公告)日：2016-11-17
申请号：US15223240
申请日：2016-07-29
Applicant: MediBeacon Inc.
Inventor： Bob O. Basore , William L. Neumann , Richard B. Dorshow , Raghavan Rajagopalan
Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.
Abstract translation: 本发明提供组织密封剂组合物和脉管系统闭合装置，其可用于光学检测组织密封和/或凝块形成。 本发明的组合物和装置包括当组合物和/或装置结合到组织密封和/或凝块中时经历可观察到的变化的光学染料，例如荧光量子产率的变化和/或视觉颜色的变化，包括 发射和/或吸收波长的变化。 本发明的组织密封剂和血管闭合装置可用于可视化密封和/或血块形成，例如，在外科手术期间或之后，导管移除之后等。本发明还提供用于组织密封的形成和光学检测的方法 或脉管系统穿刺闭合件以及可用于组织密封或脉管系统穿刺闭合件的形成和光学检测的医疗套件。
-
13.发明申请PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND METHODS OF USING THE SAME IN OPTICAL APPLICATIONS 审中-公开具有扩展结合的吡嗪衍生物及其在光学应用中的应用方法公开(公告)号：US20160090376A1
公开(公告)日：2016-03-31
申请号：US14962242
申请日：2015-12-08
Applicant: MediBeacon Inc.
Inventor： Willliam L. Neumann , Raghavan Rajagopalan , Richard B. Dorshow
IPC: C07D405/04 , C07D241/28 , C07D403/14 , A61K49/00 , C07D241/20 , C07D401/04 , C07D241/12 , C07D403/04 , C07D241/26
CPC classification number: C07D405/04 , A61K49/0021 , C07D241/12 , C07D241/20 , C07D241/24 , C07D241/26 , C07D241/28 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/06 , C07D409/10 , C07D409/14 , C07D413/04 , C07D417/04 , C07D473/18 , C07D473/34
Abstract: The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.
Abstract translation: 本发明涉及能够吸收和发出可见光和/或近红外光谱中的光谱能量的吡嗪衍生物。 本发明的吡嗪衍生物可以以药学上可接受的组合物的形式施用于患者，并用于医学（例如，诊断成像）程序中。
-
公开(公告)号：US11602570B2
公开(公告)日：2023-03-14
申请号：US16171689
申请日：2018-10-26
Applicant: MediBeacon Inc.
Inventor： Martin P. Debreczeny , Raghavan Rajagopalan , Richard B. Dorshow , William L. Neumann , Thomas E. Rogers
IPC: A61K49/00 , C07D241/26 , A61B5/20 , A61B5/00 , C09B57/00 , A61B5/1495 , A61P13/12
Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
-
公开(公告)号：US11351274B2
公开(公告)日：2022-06-07
申请号：US16289503
申请日：2019-02-28
Applicant: MediBeacon Inc.
Inventor： Richard B. Dorshow , Raghavan Rajagopalan , Dennis A. Moore , Scott T. Depierro
Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
-
Patent Agency Ranking
公开(公告)号：US10695445B2
公开(公告)日：2020-06-30
申请号：US16143682
申请日：2018-09-27
Applicant: MediBeacon Inc.
Inventor： Richard B. Dorshow , Raghavan Rajagopalan , Dennis A. Moore , Scott T. Depierro
Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
-
17.发明申请公开(公告)号：US20190194172A1
公开(公告)日：2019-06-27
申请号：US16289509
申请日：2019-02-28
Applicant: MediBeacon Inc.
Inventor： William L. Neumann , Raghavan Rajagopalan , Richard B. Dorshow
IPC: C07D405/04 , C07D241/26 , C07D241/20 , A61K49/00 , C07D401/04 , C07D473/34 , C07D473/18 , C07D417/04 , C07D413/04 , C07D409/14 , C07D409/10 , C07D409/06 , C07D409/04 , C07D403/14 , C07D403/12 , C07D403/04 , C07D401/14 , C07D241/28 , C07D241/24 , C07D241/12
CPC classification number: C07D405/04 , A61K49/0021 , C07D241/12 , C07D241/20 , C07D241/24 , C07D241/26 , C07D241/28 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/06 , C07D409/10 , C07D409/14 , C07D413/04 , C07D417/04 , C07D473/18 , C07D473/34
Abstract: The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.
-
公开(公告)号：US20190125902A1
公开(公告)日：2019-05-02
申请号：US16171695
申请日：2018-10-26
Applicant: MediBeacon Inc.
Inventor： Raghavan Rajagopalan , Richard B. Dorshow , William L. Neumann , Thomas E. Rogers
Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
-
公开(公告)号：US20190022256A1
公开(公告)日：2019-01-24
申请号：US16143682
申请日：2018-09-27
Applicant: MediBeacon Inc.
Inventor： Richard B. Dorshow , Raghavan Rajagopalan , Dennis A. Moore , Scott T. Depierro
Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
-
20.发明申请公开(公告)号：US20170298030A9
公开(公告)日：2017-10-19
申请号：US15178799
申请日：2016-06-10
Applicant: MediBeacon Inc.
Inventor： Raghavan Rajagopalan , Richard B. Dorshow , William L. Neumann , Dennis A. Moore
IPC: C07D241/28 , A61K49/00 , C07D241/20 , C07D241/26 , A61K31/4965
CPC classification number: C07D241/28 , A61K31/4965 , A61K49/0004 , A61K49/0021 , A61K49/0052 , C07D241/20 , C07D241/26
Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 of Formulas I and II may be characterized as electron withdrawing groups, while Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.023 seconds)
